SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0003319708321748v1
59/2_suppl/77S    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Toutouzas, P.
Right arrow Articles by Richter, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toutouzas, P.
Right arrow Articles by Richter, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Carotid Intima—Media Thickness (cIMT): A Useful Clinic Tool or Research Luxury? Another View of the ENHANCE Trial

P. Toutouzas, MD, FESC, FACC

Department of Cardiology, Hellenic Heart Foundation, University of Athens

D. Richter, MD, FESC, FAHA

Department of Cardiology, Euroclinic Athens, Athens, Greece, richterdimitri{at}hotmail.com

The ENHANCE trial was the first trial of ezetimibe— simvastatin with a surrogate marker as a primary endpoint. The combination of the 2 drugs is highly effective in reducing total cholesterol and low-density lipoprotein cholesterol levels and with a positive profile on high-density lipoprotein cholesterol. However, there are no data as yet about the clinical effectiveness of the addition of ezetimibe on statin therapy and whether this provides a further reduction of cardiovascular events. The answer to the clinical hard endpoints question will be provided in 2012 by the IMPROVE-IT trial comparing the effectiveness of simvastatin 40 mg plus ezetimibe versus simvastatin 40 mg on 18 000 acute coronary syndrome patients. The ENHANCE study failed in its primary endpoint, carotid intima—media thickness reduction, but has various methodological weaknesses that makes it very difficult to accept the American College of Cardiology statement that ezetimibe should be the last resort after trying all other available treatments.

Key Words: ENHANCE • carotid intima—media thickness • ezetimibe

This version was published on August 1, 2008

Angiology, Vol. 59, No. 2 suppl, 77S-79S (2008)
DOI: 10.1177/0003319708321748
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 ANGIOLOGYHome page
G. S. Goumas
LDL-Cholesterol is the King
Angiology, June 1, 2009; 60(3): 387 - 388.
[PDF]

Home page
 ANGIOLOGYHome page
G. S. Goumas
Is There Evidence-based Hypolipidemic Treatment With Clinical Benefit Beyond Statins?
Angiology, February 1, 2009; 60(1): 93 - 98.
[Abstract] [PDF]


Advertisement